UnknownN/Aketamine
Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray
Sponsored by Lukas Pezawas
NCT ID
NCT04843462
Target Enrollment
70 participants
Start Date
2021-04-29
Est. Completion
2023-04-14
About This Study
Pragmatic clinical trial of an add-on therapy regarding the use of edupression.com® - a licensed computer based self-help program - on patients with therapy-resistant depression receiving esketamine nasal spray
Conditions Studied
Interventions
- •edupression.com®
- •Esketamine nasal spray
Eligibility
Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Age 18 or older * Initial MADRS-Score of 22 or above * Diagnosis of a therapy-resistant depression following the definition of the European Medicines Agency (EMA) - absence of remission after two or more guideline-oriented therapies * Patients assigned to treatment with nasal esketamine spray Spravato® * Signed informed consent * Native German speaker * Basic knowledge in using computers/smartphones operationalized as daily use of at least two devices (such as tablets, computers, smartphones etc) Exclusion Criteria: * Contraindication regarding the use of Spravato® * Diagnosis of one of the following psychiatric comorbidities: substance abuse, schizoaffective disorders, schizophrenia, bipolar disorder, organic disorders diagnosed via Mini International Neuropsychiatric Interview (MINI)
Study Locations (1)
Medical University Vienna
Vienna, Austria